Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Most relevant
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Australian Stock Exchange  -  11:37:27 2023-05-29 pm EDT
0.0120 AUD    0.00%
05/11Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director
CI
02/27Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
01/30Hexima Limited Declares Voting Results
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about HEXIMA LIMITED
05/11Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director
CI
02/27Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
01/30Hexima Limited Declares Voting Results
CI
01/03Arovella Therapeutics Appoints COO
MT
2022Hexima Acting CEO to Step Down
MT
2022Nicole Van Der Weerden to Step Down as CEO of Hexima Limited
CI
2022Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office
MT
2022Hexima Limited Receives Requisition Notice from Merchant Biotech Fund
CI
2022Hexima Limited Announces Board Changes
CI
202210,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC..
CI
20226,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
CI
2022Hexima : 2022 Annual Financial Report
PU
2022Hexima Limited Announces Change of Address
CI
2022Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
2022Hexima Managing Director, CEO Steps Down
MT
2022Hexima Limited Announces Management Changes
CI
2022Hexima : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr
PU
2022Hexima Limited Announces Phase II Results of Pezadeftide
CI
2022Australian Shares Jump on IT Boost Amid Bargain Hunting
MT
2022Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive..
MT
2022Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide
CI
2022Hexima : ShareCafe Presentation
PU
2022Hexima : Notification regarding unquoted securities - HXL
PU
2022Hexima : Investor Webinar on Today
PU
2022Hexima : Application for quotation of securities - HXL
PU
2022Hexima : Appendix 4D and Interim Financial Statements
PU
2022Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2021
CI
2022Hexima : Notification regarding unquoted securities - HXL
PU
2022Hexima : Application for quotation of securities - HXL
PU
2022Hexima : Quarterly Activities Report and Appendix 4C
PU
2022Hexima Appoints Commercial Chief
MT
2022Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021Hexima : Notification regarding unquoted securities - HXL
PU
2021Hexima : Notification regarding unquoted securities - HXL
PU
2021Hexima Names New Chief Development Officer
MT
2021Hexima : CEO's Presentation
PU
2021Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
2021Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso..
CI
2021Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
CI
2021Hexima Completes Oversubscribed Share Purchase Plan
MT
2021Hexima : Application for quotation of securities - HXL
PU
2021Hexima Limited Announces Company Secretary Change
CI
20213,559,437 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
CI
2021Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 Septembe..
CI
2021Hexima : 2021áAnnual Financial Report
PU
2021Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
2021Hexima Limited Auditor Raises 'Going Concern' Doubt
CI
2021Hexima : Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surge..
MT
2021Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging
CI
2021Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial
CI
2021Hexima : Expects to Secure European Patent for Nail Fungal Infection Treatment
MT
2021Hexima Limited Extends Its Patent Protection for Pezadeftide
CI
2021Hexima : Fungal Nail Infection Treatment Receives INN Designation
MT
2021Hexima : Secures Patent for Fungal Nail Infection Treatment
MT
2021Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 ..
CI
2021Hexima : R&D Webinar on TodayOpens in a new Window
PU
2021Hexima : SAB Formation and R&D Video ConferenceOpens in a new Window
PU
2021Hexima : Half Year Report and AccountsOpens in a new Window
PU
2021Hexima Limited Announces Earnings Results for the Six Months Ended 31 December 2020
CI
2021Hexima Limited Updates Timeline to Phase 2B Results
CI
2020Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.
CI
2020Hexima Limited Reports Earnings Results for the Year Ended June 30, 2019
CI
2020Hexima Limited has filed an IPO in the amount of AUD 7.5 million.
CI
2020Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2020
CI
2020Hexima Limited Auditor Raises 'Going Concern' Doubt
CI
2020Hexima Limited announced that it has received AUD 5.5 million in funding
CI
2019Hexima Limited Auditor Raises 'Going Concern' Doubt
CI
2012Hexima Limited Announces Unaudited Consolidated Earnings Results for Six Months Ended D..
CI
Upcoming event on HEXIMA LIMITED
-40% off: Our subscriptions help you unlock hidden opportunities!
Subscribe
fermer